Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Optimized benzoxazolone carboxamides for oral treatment of neurological lysosomal storage diseases

May 25, 2020

Administration of scAAV9.CLN8 shows promise for treating CLN8-driven Batten disease

May 21, 2020

Janssen Pharmaceutica discloses SGLT2 inhibitors

May 21, 2020

Topline phase I data and interim phase I/II results presented for Trappsol Cyclo in NPC1

May 21, 2020

Janssen discovers novel potent EP inhibitors

May 19, 2020

Daiichi Sankyo, Sanford Burnham Prebys patent AP-TNAP inhibitors

May 15, 2020

Novadip reports interim data from phase I/II bone non-union study of NVD-003

May 15, 2020

Copper escort alleviates Menkes disease

May 14, 2020

miR-802 overexpression links obesity with impaired insulin transcription and secretion

May 13, 2020

Boehringer Ingelheim studies BI-456906 for type 2 diabetes in new phase II trial

May 12, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...